arrow
E

EnsomMaryH.H

UniversityofBritishColumbia
H指数:0
被引数:0

个人简介

"Dr. Ensom earned her BS(Pharm) degree in 1977 and PharmD in 1985, both from the University of Kentucky (UK). In between degrees, she was a hospital pharmacist and developed clinical services in South Carolina, Washington, and Kentucky. She completed a postdoctoral fellowship in clinical pharmacokinetics at UK in 1987, served on the faculty at the UK College of Pharmacy and as director of the Clinical Pharmacokinetics Service at the UK Chandler Medical Center for 10 years (1987–97) before joining the Faculty at UBC in 1997 where she served as director of the UBC PharmD program for 10 years (2002–12). Dr. Ensom has 503 publications (including 233 articles in peer-reviewed journals, 222 research abstracts, three books/monographs, 12 book chapters, and over 30 other works) to her credit. Aside from PharmD students, she has supervised and co-supervised over 100 hospital pharmacy residents, MSc students, PhD students, and postdoctoral fellows. Dr. Ensom has received more than 75 awards for scholarship, research, and service, including 10 outstanding teacher awards. She is one of only 34 distinguished university scholars at UBC. In addition, Dr. Ensom is the only Canada-based recipient of the Education or Publication Award from the American College of Clinical Pharmacy (ACCP), a U.S.-based international organization with more than 15,000 members. She is the only Canada-based recipient of the Award for Sustained Contributions to the Literature from the American Society of Health-System Pharmacists (ASHP), a 40,000 plus member, U.S.-based international organization. She is an elected ACCP Research Institute Trustee, recipient of the Paul F. Parker Award from the UK Pharmacy Residency Program for \"an individual who has displayed sustained contribution to the profession in practice, teaching or research; a commitment to high ideals and excellence in their chosen field; leadership and innovation; and a passion to encourage the personal and professional growth of others,\" and member of the inaugural class (n=4) of the Hall of Distinguished Alumni, UK College of Pharmacy. Dr. Ensom is editor for the Canadian Journal of Hospital Pharmacy and serves on the editorial boards of five other journals. She is a fellow of ASHP, ACCP, and the Canadian Society of Hospital Pharmacists (CSHP), and the Canadian Academy of Health Sciences (CAHS)."

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

暂无数据

研究方向

What distinguishes Dr. Ensom's translational (bedside to bench to bedside) research program from most others' in the Faculty is that it is both clinical and laboratory-based. Dr. Ensom's long-term research focus has been in clinical pharmacokinetics and pharmacodynamics (particularly as these disciplines relate to: women's healtheffects of gender, age, and other pathophysiologic states on pharmacokinetics and pharmacodynamicsand novel approaches to therapeutic drug monitoring), with more recent interests in pharmacogenetics and pharmaceutical outcomes evaluations. Every day, Dr. Ensom uses her clinical practice experiences to identify relevant pharmacokinetic/pharmacodynamic/ pharmacogenetic problems that are then studied in the laboratory. As such, her research teams (specific for each project) consist of clinicians, laboratory scientists, and a full array of trainees (BSc, MSc, PharmD, and PhD studentspharmacy residentsand postdoctoral fellows). As an integrator who bridges the gap between the basic and clinical sciences, the goal of Dr. Ensom's translational research program is to address clinical problems from a qualitative, quantitative, and mechanistic perspective and to make a difference in the health and well-being of patients (i.e., study results are directly and immediately incorporated into patient care). Her research program has received more than 140 government, foundation, and industry grants totaling more than $7 million. Current projects include: Immunosuppressant Pharmacokinetics, Limited Sampling Strategies, and Pharmacogenetics Characterizes the pharmacokinetics of (and develop limited sampling strategies for) mycophenolate and tacrolimus in lung, heart, kidney, and islet transplant recipients and ascertains the contribution of genetic polymorphisms (e.g., UGT and ABCC2) and other factors to inter-patient variability in pharmacokinetics of mycophenolate and its glucuronidated metabolites. Impact of Various Pathophysiologic Conditions on Pharmacokinetics and Pharmacodynamics Evaluates the pharmacokinetics/pharmacodynamics of various drugs in patients with various pathophysiologic conditions (e.g., intravenous immunoglobulin in patients with recurrent pregnancy loss, prior to and during pregnancy, and in patients with other immunologic conditions). Stability of Medications in Extemporaneously Prepared Formulations for Use in Pediatric and Other Patients Evaluates the stability of various extemporaneously-compounded oral and intravenous formulations and apply the results immediately to care of pediatric and other patients. Dr. Ensom is also contributing to various other pharmacokinetics/pharmacodynamics/pharmacogenetics, and pharmaceutical outcomes studies as co-investigator.
暂无数据